Clinical trials: Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis Relapse
Evaluation of Relapse Presence in Multiple Sclerosis
Purpose: This study aims to investigate the demonstrability of increased inflammation and neurodegeneration in multiple sclerosis (MS) patients in relapse period compared to MS patients in remission by cross-sectional analysis of…
- Trial name
- NCT05218317
- Testing
- in-vivo Corneal Confocal Microscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Marmara University
Multiple Sclerosis, Remitting Relapsing Multiple Sclerosis
Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis
Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults.
- Trial name
- MODIF-MS (NCT06330077)
- Testing
- Ifenprodil
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Relapsing-Remitting
Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM
The purpose of the research study is to investigate whether the extent and severity of lesions in the brain as measured by special MRI techniques can distinguish between Multiple Sclerosis (MS) patients with or without memory…
- Trial name
- NeuroQuant (NCT05684016)
- Testing
- NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- George Washington University
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple Sclerosis
The goal of this prospective observational cohort study is to determine the frequency of progression independent of relapse activity (PIRA) and identify its clinical, radiological, neuroaxonal, and functional predictors in…
- Trial name
- RRMS (NCT07762040)
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Sclerosis
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple…
- Trial name
- NCT00246324
- Testing
- Interferon beta 1a, oral doxycycline
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Multiple Sclerosis, Relapsing-Remitting
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota…
- Trial name
- NCT03975413
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Multiple Sclerosis, Relapsing-Remitting
Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis
Multiple Sclerosis (MS) is the most common acquired neurological disease leading to disability, especially ambulatory, in young adults.
- Trial name
- MS-TRACTS (NCT04220814)
- Testing
- MRI, Electrophysiology
- Where
- 2 sites in France
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis
The aim of the study is to investigate reliability, validity, and responsiveness of the timed 360° turn test in patients with Multiple Sclerosis.
- Trial name
- NCT03718026
- Testing
- The timed 360° turn test
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Gazi University
Relapsing Remitting Multiple Sclerosis
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning.
- Trial name
- NCT00914758
- Where
- 7 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington Neuropsychology Research Group